| | | |
100 × CD4+CD25+/CD4+ (N)
|
|---|
|
Treatment
|
Expt no.
|
Organ
|
IFN-γR KO
|
WT
|
|---|
|
Naive
|
1
|
Thymus
|
3.2 ± 0.6 (5)
|
2.2 ± 0.7 (5)
|
| | |
Spleen
|
10.1 ± 0.9 (3) *
|
7.4 ± 0.2 (3)
|
| | |
Lymph nodes
|
6.9 ± 1.1 (5)
|
5.1 ± 1.1 (5)
|
| |
2
|
Spleen
|
14.4 (1)
|
9.9 (1)
|
| | |
Lymph nodes
|
9.1 ± 0.9 (4)
|
6.6 ± 0.7 (4)
|
| |
3
|
Lymph nodes
|
11.2 (1)
|
7.0 (1)
|
|
CIA
|
4
|
Thymus
|
3.5 ± 0.9 (3)
|
4.0 ± 1.6 (3)
|
| | |
Spleen
|
11.0 ± 1.3 (2)
|
7.9 ± 0.7 (2)
|
| | |
Lymph nodes
|
10.2 ± 0.8 (6)
|
7.7 ± 0.6 (6)
|
| |
5
|
Spleen
|
12.1 ± 2.9 (3)
|
9.2 ± 0.8 (3)
|
| | |
Lymph nodes
|
12.9 ± 1.4 (4)
|
10.3 ± 1.1 (4)
|
| |
6
|
Lymph nodes
|
13.4 ± 0.4 (4) *
|
9.2 ± 0.7 (4)
|
- Cells were obtained from thymuses, spleens or lymph nodes of IFN-γ receptor knock-out (IFN-γR KO) and wild-type DBA/1 mice. In experiments 4 to 6, mice were immunised with collagen type II in complete Freund's adjuvant on day 0, and cells were obtained on day 21 (collagen-induced arthritis; CIA). Cells were stained with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4 antibodies. The proportion of CD4+CD25+ in the total CD4+ T cell population is shown. In experiments 1, 2, 4 and 5, N (number in parentheses) indicates the number of mice in each experiment; in experiments 3 and 6, N represents the number of experiments, each consisting of groups of 5 to 10 mice, from which samples were pooled for analysis. *Significant difference between IFN-γR KO and wild-type mice (P < 0.05; Mann–Whitney U-test).
